SLC2A5

Across TCGA pan-cancer cohorts, SLC2A5 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SLC2A5 data layer compared with 23 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SLC2A5 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SLC2A5 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LSCC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where SLC2A5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	III,IV	0.360	0.773	.029	8	view →
CCRCC	DFS	Median	III,IV	0.928	0.128	.014	8	view →
LUAD	OS	Quartile	II,III,IV	0.373	0.805	.025	2	view →
LSCC	OS	Median	II,III,IV	1.000	0.905	.020	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SLC2A5–PDAC (OS)

Open the PDAC breakdown →